Angelini Ventures
"Innovation that matters": Regina Hodits on venture capital, differentiation, and the future of life sciences
Dr. Regina Hodits, Managing Director of Angelini Ventures, was interviewed for Issue 1/2026 of Plattform Life Sciences, alongside 30 leading investors reflecting on capital allocation trends, risk management, and the evolving standards of the European life sciences market.
In the interview, Regina outlines Angelini Ventures' investment philosophy — from its focus on independent innovation in CNS, oncology, and healthtech, to its hands-on approach to clinical development strategy.
Innovation needs an environment that rewards risk-taking, enables international connectivity, and makes long-term capital commitment attractive.
Regina Hodits,
A compelling read for anyone navigating the current funding landscape.
The full article (in German) is available here: https://www.goingpublic.de/wp-content/uploads/epaper/epaper-Life-Sciences-1-2025/#28